11 ms·
Last-resort cancer therapy holds back disease for more than a decade
- pseudolus 5y agoThe New York Times recently ran a story about the same therapy. [0]. [0] https://www.nytimes.com/2022/02/02/health/leukemia-car-t-immunotherapy.html https://www.nytimes.com/2022/02/02/health/leukemia-car-t-imm...
- omarhaneef 5y agoI don't understand why they can't do it again if a person relapses. Why is it a one time only event? Or, to put it another way, when the efficacy wears off, why does it persist?
- justsocrateasin 5y agoThis may be an oversimplification, and I could be wrong, but the way I understand it is this: Relapse events are often triggered by an alternative mutation in the cancer. So let's say your skin cell becomes cancerous because gene 1111 mutates. You have, let's say, a million other genes that dictate your skin cell, and maybe like a few dozen mutations that could be cancerous (some mutations are harmless). So the T cell targets that gene 1111 mutation, but as a response, either that same mutated cell mutates again, or a healthy cell mutates. Now it's gene 1232 that mutates, but your T cells are modified to only recognize that gene 1111 mutation, so the new gene 1232 mutation sneaks by without being killed by the T cell. There are a lot of intuitions I have about why you can't just do it again, and ultimately I think it depends. Maybe gene 1232 doesn't change a protein that T cells can target without killing your other cells. Maybe your skin cell has dozens of mutations but 99% of them aren't cancerous, and we don't yet have the right signal/noise reduction in sequencing / the right AI to determine the mutation that is causing the cancer. Here we need to keep in mind that these proteins are very small and very hard to determine the structure of. Cancer cells can be very hard to differentiate from normal cells in a way that you can target them, so a new mutation is a whole new puzzle to solve. If I am wrong please correct me - my degree is in chemistry / applied math and not genetics/biology and this info comes from domain knowledge I pick up at my job (SDE for a cancer company) + books I've read.
- omarhaneef 5y agoSo let's say you're targetting cd19 (the protein). You're saying that the target might stop emitting cd19. Okay, but then why not target cd21 or another target that the cancer is emitting, and run CAR-T again?
- arjvik 5y agoSometimes the cancer doesn't emit any marker proteins, or maybe the ones it does are difficult to detect/create antibodies to bind to. (I'm in the same situation as 2 above, I'm a software engineer with domain knowledge from working in a cancer research lab at a university; I may be entirely wrong.)
- PeterisP 5y agoYou need to choose a marker that you can "afford" to use for destruction - which either doesn't exist at all in healthy cells, or, more likely, it exists but losing all your healthy cells with the same marker won't kill you (but is still likely to harm you, just in ways that can be treated). Such markers are scarce, and not guaranteed to exist; if we find one for this cancer (like CD19) that works, but if it fails, then it's exceedingly likely that targeting "cd21 or another target" will simply kill you because it will also destroy some vital cells in your liver or veins or brain.
- omarhaneef 5y agoYou typically have a choice of a few “safer” markers like cd19, 21, 22 etc Even 19 will knock out your B cells and has to be managed with various treatments.
- s1artibartfast 5y agoMy understanding is a little different: All skin cells have gene 1111, and you CAR-T goes after cells expressing gene 1111, killing all your skin. Some of the cancerous skin cells mutate to not express gene 1111, evading the CAR-T efficacy.
- mlyle 5y agoShort, incomplete answer: Cancer evolves. After a therapy has failed, you've effectively selected the proportion of the cancer most resistant to that therapy.
- inter_netuser 5y agocan't it be sequenced again and again and custom treatment prepared every time? cancer in general an umbrella term for 100s of different diseases.
- mlyle 5y agoIt all comes down to what surface receptors the cancer is presenting on whether you can get T cells to attack it. If the B-specific receptors are gone on your B-cell lymphoma, there may not be a great target left that isn't also on a bunch of cells you need. Each thing you do that targets "weird" characteristics of cancer (or bacterial infection, or pests) selects for cancer (or bacteria, or pests) that is presenting as less weird relative to everything else around.
- f6v 5y agoOne reason would be that CD4 and CD8 populations undergo major changes with age. There’s a shift towards exhausted phenotype. Immune system produces fewer and fewer naive T cells in the bone marrow, thymus is less efficient in adulthood as well. I’d imagine CAR-Ts are less efficient in older adults. So getting in relapse after a decade would put a patient in a different position.
- polski-g 5y agoLuckily you can still go with a bone marrow transplant.
- doctoring 5y agoThere's a couple of reasons for why a person may relapse after CAR-T therapy, and much is still under investigation. One large category is that the attack on the CD19 target has selected for B-cells which have a mutated CD19 or do not express CD19. This part kind of makes sense, and is somewhat understandable. The other category is roughly that the CAR-T cells fucked up, and this is where things are a little murky. Sometimes the CAR-T cells kind of disappeared really quickly after infusion. Sometimes they're there but there's no significant immune response. Remember the therapy uses the patient's own T-cells which get "armed" outside the body and then re-infused. What if the patient's own T-cells are kind of uh, wimpy? Or their immune system overall is? (We know, for example, that T-cell immunity in general declines over age, which probably partly explains better results in younger patients than older). Anyways, for various reasons, you can see why just "doing it again" may not work due to some issue with the targeting and the immune reaction. Oh and also CAR-T therapy is not benign. You can get intense cytokine release syndrome where the (intended) activation of your immune system causes a ton of systemic effects (sometimes resulting in organ failure, seizures, death). Nevertheless, sometimes they do try it again. I've had patients they've attempted CAR-T two or three times on. As you may guess, it was not effective.
- omarhaneef 5y agoIt seems it would be effective if the B-cells were still emitting CD-21 or some other target. I thought that they manage the CRS pretty well these days. Is it still a major risk? I would be very curious to know more about this wimpy or no response. I am doubly surprised that it doesn't help to just do more.
- doctoring 5y agoChoosing another target is a good idea! But, as you can imagine, we've been trying a lot of targets and they don't seem to work as well. One issue is that CD19 is the only known target that is a) expressed throughout the entirety of the B-cell lifespan, b) fairly preserved under immunological pressure, and c) is not expressed on other cells. Other targets do not maintain those characteristics and as such either won't catch all the tumor cells or will catch too many other cells. (CD21, for example, is also expressed on T-cells.) That being said, there are studies ongoing for some of these targets in like "last last resort" capacity, as well as certain dual-target CAR-Ts looking at CD19 + another (CD22 or CD123, for example), to try to widen the net while tolerating a degree of on-target but non-tumor effects. One could also imagine a way to more rapidly alter a patient's CAR-Ts such that you could quickly switch targets, or update them if their malignant CD19 was mutating. Currently the manufacture and production of CAR-T cells is very slow and expensive process, but I do have some friends working on improving that. Some are also working on the idea of a sort of "blank slate" CAR-T cell line which could be used in anybody, rather than being harvested from the particular patient in question. re: CRS. It is still a significant risk, but our understanding has definitely dramatically improved over the past 10 years. We're getting better and better at anticipating, appropriately triaging, and providing necessary diagnostics & supportive care. That being said, severe outcomes and death do still occur. I don't know the numbers, to be honest. re: the wimpy response. I am less well-versed in the immunological complexities but there are just so many steps which could contribute. Part of the CAR-T cell success requires them to continue to clonally expand after infusion into the body, and sometimes after infusion they just... don't. Or only a tiny subpopulation of them does. Why? We're not sure. Sometimes they fail to recruit the body's immune response. Why? Also not sure. Maybe it has to do with the health of the T-cells when they were harvested? Maybe something went wrong with the CAR engineering? Maybe with the host immune system? Here's a decent overview of some mechanisms of relapse after CAR-T which might be a good jumping off point: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863137/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863137/
- dna4cy 5y agoIn addition to what others have written (mainly, loss of tumor antigen target CD19) the antigen receptor (part of the CAR) can be recognized as foreign (FMC63 on human CD19 targeting CARs is mouse origin) and the body will generate an antibody response to it. Thus, the second time CAR-T is infused, they are quickly rejected.
- diskzero 5y agoOther good answers are here about additional mutations occurring, making the cells no longer receptive. Another reason is that receiving CAR-T itself is quite risky. Almost everyone experiences some level of neurotoxicity, decreased cognition and more. It is my hope that these negative effects caused by the treatment will vanish, as CAR-T itself is pretty amazing.
- elromulous 5y agoJust an fyi - while car-t is very promising in many ways, it has not been effective against solid tumors. Last time I looked into this (while my father was still alive and battling cancer, 2020), attempts to get car-t to be more effective against solid tumors have failed pretty consistently. This is why you only see car-t mentioned with leukemias, lymphomas, etc. Side note: If you're reading this because you're desperately looking for cancer treatment for a loved one, keep looking! I can share my personal anecdote if folks are interested, but the tldr is that my own searching ended up being fruitful and resulting in treatment that extended my father's life (pain and side effect free!). And without my insistence, the doctors treating him would have simply followed the conventional treatment (the dreaded FOLFIRINOX).
- aantix 5y agoWould love to hear your story and the specifics of his alternate treatment. Thank-you for sharing your story.
- elromulous 5y agoThis is a much abbreviated version of the story. My father was diagnosed with Ampulla of vater carcinoma. It's a pretty rare cancer, most similar to pancreatic cancer. After the curative options had been exhausted (read: cancer returned after surgery), the oncologist started a regimen of abraxane and one other chemo agent (I'm blanking on the name right now). These of course come with their share of side effects, as they are "classic" chemo. Not to mention their efficacy is pretty terrible. But really at this point we needed more data. They had never sequenced the tumor. Many, many emails and calls later, the doctor finally agreed to order the sequencing. Till this day I don't know why there was so much resistance to this (also keep in mind, this wasn't some rural hospital, this was at Johns Hopkins). Some time goes by and we finally get the results. The results showed a brca mutation. This was of course excellent news, as the brca mutations are very widely studied due to their connection with breast cancer. After some research, it turned out parp inhibitors were the latest most effective treatment at the time, specifically Lynparza. Again, many emails and calls, until the oncologist agreed to prescribe it. And unlike the conventional chemo agents, this was taken orally and had few if any side effects. Months go by and the ct results come in - the tumors are shrinking! All in all my father remained in remission under the parp inhibitors for a little over a year, side effect and pain free (I can't stress that last part enough). Lynparza eventually stopped being effective (this is believed to occur due to the cancer mutating). We subsequently tried a clinical trial but in the end the battle was lost, and my father passed. While the parp inhibitor wasn't a cure, my father, my family, and I, would not give up that extra year for the world. So the tldr is: don't just listen to the oncologist, get a second opinion, don't be afraid to read hundreds of medical papers, and definitely badger the oncologist if you have salient information. Edit: typos
- doctoring 5y agoCAR-T therapy is incredibly complex and incredibly cool. One of the reasons CAR-T therapy has been so successful thus far with certain lymphomas and some leukemias is that there is a specific surface protein (CD19) which is expressed in all B-cells (the deranged lineage in the case of lymphoma) and is also not expressed by any other cells in the body. By engineering a patient's T-cells to target CD19, you create a highly sensitive and specific attack that recruits their own immune system to annihilate the entire B lineage population. One problem we run into when trying this for other cancers (like, that don't come from B-cells) is that it's been really hard to find such a nicely specific surface protein, as well as an entire population of cells you can just annihilate and be survivable for the patient. Most surface proteins are expressed in varying degrees throughout various different organs in the body, so a CAR-T against it would cause a ton of off-target effects. In some early trials for certain cancers they encountered this with unfortunate side effects (including in some cases death). Nevertheless, there is lots and lots of research still ongoing in the field, which is super exciting, from trying out previously unknown targets, to figuring out how to better produce the T-cells, to enhancing the resultant immune response cascade, etc etc.
- f6v 5y agoNot familiar with tumor immunology but I’d imagine it could be challenging to get CAR-Ts to infiltrate the tumor on demand.
- metiscus 5y agoNot a medical guy but ipilimumab and friends may help do that. They blockade ctla-4 which downregulates cd4 activity. A combination may result in enhanced results.
- est31 5y agoThis destroys all your B-cells in your body, right? That means the B-cells aren't available for normal operation any more, right? I guess it's better to be immuno compromised than dead...
- 5y ago
- sam537 5y agoSimplify it like this: T-cell: very effective at killing; not as good at recognizing specific things. Antibodies: not that effective at killing; excellent at specifically recognizing things. CAR-T: Let's stick an antibody against X (eg CD19, CD22) to a T-cell surface so it can recognize with the antibody and kill with its innate capacity to kill. Ta da! It's fascinating, it is changing hematologic oncology. The bad news is, as always, the price and the manufacturing time (2-8 weeks). This last part seems to be getting better.
- aledalgrande 5y agoThank you, this is a very good TLDR.
- deleted 5y ago[deleted]
- rdedev 5y agoI've had this thought that natural ability to fight of cancer cells was a precision/recall problem for the cells. Good to see that the body has ways to approach this problem. Really cool to see us use antibodies to really improve the recall
- spopejoy 5y ago> The bad news is, as always, the price It's my understanding that this is no longer _actually_ a $600,000K+ price tag anymore but that drug firms are now in the "profit recouping" phase. Decide for yourself if that's the way it should be but the good news is that it definitely will not be insane forever.
- AtlasBarfed 5y agoI know that "cancer" isn't actually one disease, it is a cacophony of different gene expressions in different tissues. Immunotherapies like this IMO show the real issue with "curing" the disease: there won't be a one-size-fits-all pill to pop that will work. Instead we may need individualized/highly customized medicine. Alas this might not be in the "profit profile" of a typical pharma company. So it might cost 250,000$ to cure cancer, but it is a CURE, genetically specific to your cancer and genetics. Not a perpetual therapy like the phama execs like. That may take an army of lab workers, or some pretty interesting lab equipment. But the payoff is great. FORTY PERCENT of Americans will be diagnosed with cancer in their lifetimes.
- uf00lme 5y agoA universal cancer treatment seems like the holy grail, it may never happen but I like to have hope that science will find it e.g., https://www.nature.com/articles/s41590-019-0578-8.epdf https://www.nature.com/articles/s41590-019-0578-8.epdf
- busyant 5y agoJimmy Carter hasn't received CAR-T therapy afaik, but he's gotten other recently developed immuno modulatory anticancer therapy --pd1 inhibitors-- and I suspect that's a big reason for him still being alive. I can say the same for a family friend who probably had 6 months to live w advanced prostate cancer (this was about ten yrs ago). Shortly after his prognosis a new prostate cancer drug--xtandi-- was approved and he lived another 5 years. Many anticancer drugs have incremental benefit, but some recent advancements have been revolutionary.
- Agingcoder 5y ago'In the beginning, only about 25-35% of CAR-T cell recipients with chronic lymphocytic leukaemia experienced a complete remission of their cancer, says Porter.' I'm not very familiar with pharma success rates, but isn't complete remission for 30% of virtually dead patients already an incredibly good result?
- deleted 5y ago[deleted]
- mmettler 5y agoELI5: will this work on other types of cancers? For example, breast cancer, non small-cell lung cancers, etc.?
- trynewideas 5y agoevery time I see a headline like this I always ask - which cancers - for whom - what's the trial size - what's the success rate - what's the cost the article answers some, to some degree: - for "leukaemias, lymphomas and myelomas" - not many; "relatively few US centres are capable of delivering it", "For people with lymphoma, the figure is around 1 in 5" people who could benefit are receiving it [1] - "tens of thousands" - "only about 25-35% of CAR-T cell recipients with chronic lymphocytic leukaemia experienced a complete remission" - as of 2021 per Prime Therapeutics, "Although the wholesale acquisition cost of chimeric antigen receptor (CAR) T-cell therapies to treat B-cell lymphoma is $373,000, a new study by Prime Therapeutics of real-world data found that the total cost averages more than $700,000 and can exceed $1 million in some cases." [2] [1] https://www.nature.com/articles/d41586-020-02675-w https://www.nature.com/articles/d41586-020-02675-w [2] https://www.pharmacytimes.com/view/study-finds-total-cost-of-care-for-car-t-post-treatment-events-can-exceed-1-million https://www.pharmacytimes.com/view/study-finds-total-cost-of...
- mft_ 5y ago> - "only about 25-35% of CAR-T cell recipients with chronic lymphocytic leukaemia experienced a complete remission" Not sure why you picked CLL, which is but one of several diseases that CAR-Ts have been tested against, and which is so far unapproved. Response rates do vary, but are higher than you quote in B-ALL and DLBCL (the diseases that CAR-Ts were first approved for) 83% in B-ALL: https://www.nature.com/articles/nrd.2017.196 https://www.nature.com/articles/nrd.2017.196 82% in ref DLBCL: https://www.nejm.org/doi/full/10.1056/nejmoa1707447 https://www.nejm.org/doi/full/10.1056/nejmoa1707447 64% in DLBCL, 71% in FL: https://www.nejm.org/doi/full/10.1056/NEJMoa1708566 https://www.nejm.org/doi/full/10.1056/NEJMoa1708566
- 3D25157725 5y agoFor those interested in some of the history of immunotherapy, and cancer treatments more generally, I recommend Dr Peter Attia's excellent interview[1] with Dr Steven Rosenberg. Dr Rosenberg is Chief of Surgery at the National Cancer Institute, and was on the ground floor and helped pioneer the use of immunotherapy in fighting cancer[2]. [1] - https://www.youtube.com/watch?v=pVMl0LgdnOU https://www.youtube.com/watch?v=pVMl0LgdnOU [2] - https://en.wikipedia.org/wiki/Steven_Rosenberg https://en.wikipedia.org/wiki/Steven_Rosenberg
- aszantu 5y agoSomeone I know is expected to be dead by the end of the year. How do I go about to get this to her?
- Incerto 5y agoIf anybody is interested, there was a phenomenal documentary made a few years back, about the early clinical trials of CAR-T therapy for Leukaemia students. "War in the blood" https://www.bbc.co.uk/programmes/m0006nzt https://www.bbc.co.uk/programmes/m0006nzt
- Incerto 5y ago*studnets = patients. Typo